Ocrelizumab is associated with increased risks for infection and hospitalization among older adults with multiple sclerosis, ...

Late-breaking data from positive Phase III REMODEL-1/-2 trials will show efficacy and safety profile of remibrutinib in RMS ...

If ongoing studies demonstrate favorable safety and efficacy profiles, CAR T-cell therapy may establish a novel treatment ...

A new meta-analysis of thirteen randomized controlled trials finds that vestibular rehabilitation improves balance, gait, ...

Multiple sclerosis study reveals strengths in primary care knowledge but gaps in diagnosis and relapse treatment.

Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing ...

A new single-cell and animal study links SLC7A11-high astrocyte states to antioxidant failure and synaptic remodeling in ...

Multiple Sclerosis (MS) imposes a significant psychological burden that adversely affects patients’ subjective well-being (SWB). A primary psychological stressor in this population is the Fear of ...

Multiple sclerosis is a chronic disease where your immune system starts attacking your brain and spinal cord. The number of people living with the condition has grown to 913,925—current estimates ...

Multiple sclerosis occurs when a person’s immune system is triggered to attack the myelin sheath—a protective coating surrounding nerve cells in the central nervous system (CNS). The CNS is made up of ...